Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

Not yet recruiting

Phase 1/2 Results N/A

Summary of Purpose

Administration of cell-free exosomes derived from mesenchymal stem cell (MSCs) can be sufficient to exert therapeutic effects of intact MSCs after brain injury. In this study we aim to assay the administration of MSC derived exosome enriched by miR-124 on improvemen of disability of patients with acute ischemic stroke

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 13 February 2018.

17 Mar 2018 29 Nov 2017 17 Jul 2018 17 Jan 2019 1 Feb 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available